undamentalytics Newsletter
Sign in

Bicara Therapeutics Inc. (BCAX) stock

Add to watchlist

Add holding +

NASDAQ: BCAX Nasdaq Biotechnology Next results ~November 10, 2026

Bicara Therapeutics Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders1 buying, 4 selling1 purchase and 57 sales by directors and officers, last 12 monthsInsider trades
  • Funds102 adding, 48 cuttingOf 29 active managers that changed their stake, 18 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Next results ~November 10, 2026 (estimated)

Current signal Free cash flow diverging from earnings: TTM free cash flow fell 33.9% while net income fell 80.5%: a 47pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Bicara Therapeutics Inc.'s latest figures clears our strength thresholds.

Things to watch

  • Results due soon. Results are expected around 9 November; the share price can move sharply on the day.
  • Volatile shares. Over the past year the shares showed annualised volatility of 71% and a beta of 1.0 against the S&P 500.
  • Heavily shorted. 21.7% of the shares available to trade are sold short (12.4 days of average volume to cover).
  • Missing expectations. Earnings per share fell short of the consensus estimate in 3 of the last four quarters.

Latest results

Earnings per share
-$0.82 against an average estimate of -$0.83: beat by 0.6%
Share reaction
-11.2% in the first session after the results on August 11, 2026, against -0.1% for the S&P 500
Next report
November 10, 2026; average EPS estimate -$0.82

Bicara Therapeutics' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-13.1%
  • 1 week-53.0%
  • 1 month-55.0%
  • This year-52.9%
  • 1 year-51.2%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Earnings

Last results
August 11, 2026
Next results (est.)
November 9, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Agreement
  2. Results
  3. Leadership

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Bicara Therapeutics Inc. valuation models and calculator

No model value for Bicara Therapeutics Inc. at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: limited reported history: available models are shown without a Buy/Hold/Sell rating.

Valuation models

We value Bicara Therapeutics Inc. as an operating company, with every model that fits that kind of business. Cost of equity 10.3%: the 10-year Treasury yield (4.9%) plus a beta of 1.18 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. — Does not apply: no positive revenue in the latest twelve months
Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. — No model applies: the filings don’t yet support a value.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Bicara Therapeutics Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 10, 2026, before the open. Analysts expect revenue of $0 and EPS of −$0.82 (range −$0.97 to −$0.42) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$3.39 −35% — 0%
Next −$3.49 −3% — 0%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −2.5% on 90 days ago. In the last 30 days, 8 analysts raised Bicara Therapeutics Inc.'s forecast and 3 cut it.

Consensus EPS forecast Bicara Therapeutics Inc., last 90 days
−$4.00 −$3.00 −$2.00 −$1.00 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$3.48 Current fiscal year, 60 days ago: −$3.36 Current fiscal year, 30 days ago: −$3.39 Current fiscal year, 7 days ago: −$3.39 Current fiscal year, Now: −$3.39 −$3.39 Next fiscal year, 90 days ago: −$3.63 Next fiscal year, 60 days ago: −$3.44 Next fiscal year, 30 days ago: −$3.52 Next fiscal year, 7 days ago: −$3.52 Next fiscal year, Now: −$3.49 −$3.49

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$3.48−$3.63
60 days ago −$3.36−$3.44
30 days ago −$3.39−$3.52
7 days ago −$3.39−$3.52
Now −$3.39−$3.49

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.83 −$0.82 +0.6%
Mar 2026 −$0.65 −$0.93 −42.6%
Dec 2025 −$0.65 −$0.68 −4.0%
Sept 2025 −$0.53 −$0.67 −25.5%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

14 analysts, Oct 2026
Buy1393%
Hold00%
Sell17%

Monthly trend

  1. Oct 2026310114
  2. Sep 2026310114
  3. Aug 2026310316
  4. Jul 202639315

Counts of recommendations published by analysts covering Bicara Therapeutics Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
21.7%
of tradable shares
Days to cover
12.38
at average volume
Short interest, 1 month
−8%
to October 15, 2026
Held by institutions
—
of shares
Held by insiders
10.1%
of shares
Employees
103
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 20252026 to date
Return
BCAX−3%−53%
Industry peers (median)−5%−26%
S&P 500+18%+11%
Months that ended higher
BCAX67%36%
S&P 50075%46%
Largest fall from a high during the year
BCAX−50%−74%
S&P 500−19%−9%

Worst fall since September 13, 2024: 74% from July 7, 2026 to November 2, 2026. Getting back needed a 283% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$7.93 – $30.40
From 52-week high
−73.9%
vs 50-day average
−59.2%
vs 200-day average
−62.5%
Volatility (1 year)
71%
Beta vs S&P 500
0.99

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
4 up, 5 down
typical move ±5.9%
After a week
5 up, 4 down
typical move ±11.1%
After a month
5 up, 4 down
typical move ±17.2%
Results releasedNext dayS&P 500 next day5 days21 days
August 11, 2026 −11.2% −0.1% −10.1% −16.7%
May 11, 2026 −0.9% +0.1% −14.6% −10.5%
March 30, 2026 +8.3% +2.6% +15.9% +15.8%
February 26, 2026 −4.2% −1.0% +5.7% +4.9%
November 10, 2025 +0.6% +1.8% +2.8% +30.5%
August 12, 2025 +13.4% +1.4% +15.2% +19.9%
May 13, 2025 −3.5% +0.8% +6.0% −18.5%
March 27, 2025 +2.3% −2.3% −9.7% +13.1%
November 12, 2024 −8.8% −0.3% −19.9% −25.2%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Who owns it

Funds buying and selling
Reported value
$2.1B
Institutions reporting
170
Shares held vs prior quarter
▲ 3.1%
Positions opened / closed
35 / 10

Top buyers and sellers, Q2 2026: 102 institutions bought and 48 sold ; the biggest buyer was Blackrock, Inc (+1.0M shares) and the biggest seller Citadel Advisors LLC (−1.4M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
RA Capital Management, L.P. $215M 7.3M 10.4% 0.0%
T. Rowe Price Investment Management, Inc. $188M 6.3M 9.1% ▼ 4.0%
Siren, L.L.C. $166M 5.6M 8.0% ▼ 3.4%
Vestal Point Capital, LP $156M 5.3M 7.5% ▼ 3.2%
Deep Track Capital, LP $122M 4.1M 5.9% ▲ 0.9%
Blackrock, Inc. $114M 3.8M 5.5% ▲ 35.3%
Jupiter Topco LLC $94M 3.2M 4.5% —
Red Tree Management, LLC $93.9M 3.2M 4.5% ▼ 0.2%
Tpg Gp A, LLC $89.4M 3.0M 4.3% 0.0%
Vanguard Capital Management LLC $65.8M 2.2M 3.2% ▲ 24.9%
State Street Corp $60.8M 2.0M 2.9% ▲ 44.4%
Franklin Resources Inc $58M 2.0M 2.8% ▲ 20.4%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Bicara Therapeutics Inc.'s complete shareholder register. Values are as reported by the filers ; 3 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $4.8M 1 trade by 1 insider, last 12 months Insider sales History → $9.9M 57 trades by 4 insiders · 100% under pre-set plans
Net ▼ $5.1M net selling
Insider Date Trade Shares Price Value
Cohlhepp Ryan President, COO & Interim CEO September 8, 2026 Sell pre-set plan 14,058 $22.77 $320,101
Cohlhepp Ryan President, COO & Interim CEO September 8, 2026 Sell pre-set plan 3,442 $23.43 $80,646
Cohlhepp Ryan President and COO August 10, 2026 Sell pre-set plan 18,750 $27.98 $524,625
Mazumdar Claire Chief Executive Officer August 10, 2026 Sell pre-set plan 10,000 $27.98 $279,800
Hyep Ivan Chief Financial Officer August 10, 2026 Sell pre-set plan 12,500 $27.97 $349,625
Mazumdar Claire Chief Executive Officer July 10, 2026 Sell pre-set plan 28 $29.68 $831
Mazumdar Claire Chief Executive Officer July 10, 2026 Sell pre-set plan 9,972 $28.42 $283,404
Cohlhepp Ryan President and COO July 9, 2026 Sell pre-set plan 536 $29.00 $15,544
Hyep Ivan Chief Financial Officer July 8, 2026 Sell pre-set plan 4,413 $29.82 $131,596
Hyep Ivan Chief Financial Officer July 8, 2026 Sell pre-set plan 22,757 $28.60 $650,850
Hyep Ivan Chief Financial Officer July 8, 2026 Sell pre-set plan 830 $30.31 $25,157
Cohlhepp Ryan President and COO July 8, 2026 Sell pre-set plan 4,306 $29.80 $128,319

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 9, 2026 estimated from the company's past filing pattern, not announced

  • August 11, 2026
  • May 11, 2026
  • March 30, 2026
  • February 26, 2026
  • November 10, 2025
  • August 12, 2025

Recent SEC filings

Data status

When each part of this page on Bicara Therapeutics Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Bicara Therapeutics Inc. in brief

What does Bicara Therapeutics Inc. do?
Bicara Therapeutics Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Bicara Therapeutics Inc.'s stock ticker?
Bicara Therapeutics Inc. trades under the ticker BCAX on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are Bicara Therapeutics Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are RA Capital Management, L.P., T. Rowe Price Investment Management, Inc. and Siren, L.L.C. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Are insiders buying or selling Bicara Therapeutics Inc. stock?
Over the last 12 months, Bicara Therapeutics Inc.'s directors and officers reported 1 open-market purchases and 57 sales on Form 4. The insider trading page charts every trade.
When is Bicara Therapeutics Inc.'s next earnings date?
Around November 10, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Bicara Therapeutics Inc. announces its own schedule.